Venture Investments
We are a life science venture capital investor, delivering knowledge, network, and capital to companies.
Strategy
We strive to invest in companies that develop innovative drugs, medical devices and other technologies that improve patient care. We focus on generating strong financial returns from our portfolio of venture companies.
We invest in both private and public companies from an open evergreen fund. This funding structure enables us to take a long-term perspective.
With colleagues on the ground in Copenhagen, London, Singapore, San Francisco and Boston, we are well positioned in the major global life science hubs and can quickly respond to new and exciting investment opportunities wherever they emerge.
We invest in biotechnology, medical technology and digital health companies. Within biotech we primarily invest in companies with late preclinical or clinical stage compounds. In medtech and digital health, we prioritize commercial stage companies.
We work actively with the companies we invest in by serving on the Boards of Directors. Companies can also draw on our extensive network, as well as our commercial and scientific expertise within the life sciences.
Venture Investments deployed DKK 3.6 billion in 2023, including DKK 1.4 billion invested in 15 new investments. Notable new investments include 4D Molecular, Alentis Therapeutics, BioGeneration Capital Fund V, CARGO Therapeutics, Cymabay, Fire1, Hillstar Bio, Lexeo Therapeutics, ManaT Bio, Maplight Therapeutics, Octave Health, Pureos Bioventures Fund II, Ray Therapeutics, Terremoto Biosciences and Scion Fund I.
Portfolio company milestones
CymaBay Therapeutics, Inc. announced positive results from its Phase 3 pivotal RESPONSE study.
Crinetics Pharmaceuticals, Inc. announced positive results from its Phase 3 PATHFNDR-1 study.
Disc Medicine reported positive interim data from its Phase 2 BEACON study
Vaxcyte Inc. reported positive clinical and safety data for its 24-valent Pneumococcal Conjugate Vaccine candidate.
Anthos Therapeutics, Inc. announced positive Phase 2 data.
Alentis Therapeutics received FDA fast track designation for ALE.C04.
Amolyt Pharma announced that it will initiate its Phase 3 clinical trial of eneboparatide.
Exits and IPOs
Venture Investments exited 16 investments in 2023, and realised DKK 3.4 billion from the sale of publicly traded stock as well as from the acquisition of several of our portfolio companies.
Venture Investments key figures
52
Number of Portfolio companies
€500m
Deployed during 2023
16
Investments exited during 2023
Our Venture Investments Portfolio
Search
Meet our team